Real-world study of zevor-cel for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how well zevor-cel (a type of cell therapy) works in real life for people with multiple myeloma that has come back or not responded to treatment. It helps doctors understand if this treatment is safe and effective outside of clinical trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have multiple myeloma that has come back after treatment or has not responded to treatment.
- You have already received a commercial version of zevor-cel (a cell therapy).
- You agree to take part in the study and sign a consent form (or a legal guardian can sign for you).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying a new treatment called equecabtagene autoleucel for people whose multiple myeloma has come back or stopped responding to other treatments. It aims to see how well this therapy works in real-world medical settings.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This study tests a new cell therapy called Eque-cel, which is designed to target and kill cancer cells in people with multiple myeloma that has returned or is hard to treat after at least three prior therapies. The treatment uses your own immune cells that are modified to fight the myeloma.
This study follows people with multiple myeloma that has come back or stopped responding to treatment, and looks at how current care is used in real life. It may include people starting talquetamab, and aims to understand outcomes and treatment patterns outside of strict experimental settings.
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
This trial tests a new treatment called BCD-248 for people whose multiple myeloma has come back or stopped responding to at least two prior treatments. It aims to see if it is safe and effective.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.